Novavax Starts Late-Stage COVID-19 Vaccine Study In Children Below 11 Years

• Novavax Inc (NASDAQ: NVAX) has initiated its Phase 2b/3 Hummingbird trial to evaluate the safety, effectiveness, and efficacy of two doses of the Novavax COVID-19 vaccine in children aged six months through 11 years after a booster at six months.

• The trial will assess the Novavax COVID-19 vaccine in infants (six through 23 months of age), toddlers (two through five years), and children (six through 11 years).

• Also Read: Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents.

• The trial is an age de-escalation trial, and age groups will be tested sequentially.

• Participants have begun dosing in the six to 11-year-old age group. The trial will also have sentinel cohorts in each age group, and cohort progression and age-de-escalation will occur after a safety review.

• The trial will seek to enroll 3,600 participants. Initial results are expected in Q1 2023.

• Price Action: NVAX shares are up 0.43% at $61.37 during the market session on the last check Thursday.

See more from Benzinga

• Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.